Ann: AGM Presentation, page-21

I’m not comparing the tests as you keep saying.

Consumers are paying upwards of $2000 (whether that be clinicians, NDIS clients, or parents) for autism related programs/tools/screening/aides.

Why aren’t consumers willing to spend $200 on TALi? Tali has been tested in private schools, received multiple gov’t grants, put in front of decisions makers, backed by world renowned universities, partnered with google etc.

TALi isn’t hitting the mark.

Contrary to your belief the market is willing to accept digital therapy/aides etc and there are now many autism gamification tools on the market or in development.

The deal with Akilli is a step in a positive direction, but will it result in significant sales volume for TALi is yet to be seen. The upside may not be as positive as rose coloured glasses would suggest. Have Akilli or TALi provided any EndeavourRX sales volumes or associated revenue as an indicative guide for growth of Tali’s products once they are FDA approved?